Elanco Animal Health Investor Relations Material

Elanco Animal Health Inc. formerly a division of Eli Lilly, is an American company with multinational operations that specializes in animal health products and services. Elanco's portfolio includes a variety of products for both farm animals and pets, focusing on disease prevention, treatment, parasite control, and enhancing productivity in livestock. The company is headquartered in Greenfield, Indiana, and its shares are listed on the NYSE.

Elanco was initially founded as a division of Eli Lilly in 1954. Initially, the division focused on feed additives to promote growth in livestock, later expanding to include a broader range of animal health products, such as vaccines and treatments for both livestock and pets. In 2019, Elanco was divested from Eli Lilly, becoming a standalone company. Today, Elanco is one of the largest animal health companies in the world, operating in the same sector as companies such as Zoetis and Virbac.

Elanco produces products aimed at both companion animals and livestock. Its revenue is split nearly 50/50 between products for livestock and pets. Its product range for companion animals encompasses therapeutics, vaccines, parasiticides, and dermatology products. These offerings aim to address various health issues, such as flea and tick infestations, arthritis, and chronic pain, as well as supporting overall wellness. This is done both through medications, as well as through things such as anti-flea collars and similar products.

Elanco also plays a significant role in the livestock sector. The company offers a range of products and services aimed at improving the health, productivity, and well-being of farm animals such as cattle, poultry, and swine. Their portfolio for livestock includes vaccines, feed additives, antimicrobials, and products for parasite control and pain management. These products are designed to address health challenges and diseases common in livestock, enhance growth and efficiency, and ensure food safety.